Save the date: SOHO Spain 2025
SOHO will hold its first regional meeting in Spain from February 27-28, 2025, at the Rafael del Pino Auditorium in Madrid. The program
Society Updates
Cellular Therapy
Lymphoma
Aggressive B-Cell Lymphomas
Meetings / Conferences
2025 Tandem Meetings
Study questions clinical benefit of dexamethasone with axi-cel in LBCL patients
Prophylactic dexamethasone did not improve the safety or efficacy of axicabtagene ciloleucel (axi-cel) in patients with large B-cell lymphoma (LBCL), according to a
Lymphoma
CAR-T treatment access, timeliness remain issues for patients with NHL
Researchers assessed barriers to chimeric antigen receptor (CAR) T-cell therapy for patients with non-Hodgkin lymphoma (NHL) in a community-based network and found that
Multiple Myeloma
FDA accepts BLA review for Blenrep combo in relapsed or refractory MM
FDA accepts for review a BLA for Blenrep in combination with bortezomib plus dexamethasone and pomalidomide plus dexamethasone in MM.
Multiple Myeloma
Real-world study finds this triplet therapy is an option for daratumumab-refractory myeloma
A study showed that the triplet therapy isatuximab, pomalidomide, and dexamethasone (IsaPd) is an option for daratumumab-refractory multiple myeloma (MM), though the “modest”
Leukemia
News
EC approves blinatumomab in Ph-negative CD19+ B-ALL in the consolidation phase
By: Phillip McLeod The European Commission (EC) has approved blinatumomab (Blincyto) as a consolidation therapy for adult patients newly diagnosed with Philadelphia chromosome-negative,
Meetings / Conferences
66th American Society of Hematology Annual Meeting & Exposition
Myeloma
News
Video Interviews
Multiple myeloma updates with Dr. Lonial
In a video interview during the 66th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, California, Sagar Lonial, MD,
Lymphoma Roundtable
Cellular Therapy
Lymphoma
Indolent B-Cell Lymphomas
Roundtable Discussions
Video Interviews
What are future therapeutic combinations in follicular lymphoma?
In this video, the panel discusses promising future combinations in follicular lymphoma, highlighting novel agents paired with rituximab, bispecific antibodies, and CELMoDs like
Leukemia
Myelodysplastic Syndromes
News
Is unrelated cord blood better than bone marrow in haploidentical transplantation?
Haploidentical transplantation combined with unrelated cord blood resulted in superior one-year disease-free survival compared with the same transplant using bone marrow in patients
Cellular Therapy
Lymphoma
Indolent B-Cell Lymphomas
News
Liso-cel receives positive CHMP opinion in relapsed or refractory follicular lymphoma
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of lisocabtagene maraleucel (lise-cel) for